Corline Biomedical AB (OSTO:CLBIO) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 01, 2026)


OSTO:CLBIO Corline Biomedical AB OSTO:CLBIO
36 GF Score
Price kr17.95
GF Value kr4.97
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Corline Biomedical AB Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Corline Biomedical AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

OSTO:CLBIO vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Corline Biomedical AB's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corline Biomedical AB Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Corline Biomedical AB's Margin of Safety % (DCF FCF Based) falls into.


OSTO:CLBIO
36GF Score
Corline Biomedical AB OSTO:CLBIO
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corline Biomedical AB (OSTO:CLBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of kr17.95 is trading 261.2% above its estimated GF Value™ of kr4.97. GuruFocus considers Corline Biomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:CLBIO:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: kr4.97 vs. price of kr17.95 (261.2% above fair value)
  • GF Score™: 36/100 with 3 warning signs

No single metric tells the full story. See the OSTO:CLBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corline Biomedical AB Business Description

Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
36GF Score

Get the complete analysis for OSTO:CLBIO

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr17.95
Price
kr4.97
GF Value